0
0
53 words
0
Comments
Only 30% of individuals with neuroendocrine tumors rank living longer as their single top priority in treating their cancer, according to a study conducted by researchers at City of Hope. The findings, published in Journal of the National Comprehensive Cancer…
You are the first to view
https://www.healio.com/news/hematology-oncology/20230201/increased-longevity-not-top-treatment-goal-for-most-patients-with-neuroendocrine-tumors
Create an account or login to join the discussion